Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 CongressGlobeNewsWire • 04/28/26
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/26
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & ExpoGlobeNewsWire • 03/16/26
Cytokinetics, Incorporated (CYTK) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the MarketThe Motley Fool • 03/09/26
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch PlansZacks Investment Research • 02/25/26
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 02/24/26
Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to DeclineZacks Investment Research • 02/17/26
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic CardiomyopathyGlobeNewsWire • 02/17/26
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant ProgramGlobeNewsWire • 02/09/26
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and SymptomsGlobeNewsWire • 01/27/26
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of InvestorsBusiness Wire • 01/22/26
Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26